Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA and IFN-alpha for Patients with Oral Cancer (Phase I clinical study)
Phase 1
- Conditions
- Advanced or recurrent oral cancer
- Registration Number
- JPRN-UMIN000000999
- Lead Sponsor
- Department of Oral Surgery, Sapporo Medical University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 7
Inclusion Criteria
Not provided
Exclusion Criteria
1) prior cancer therapy, such as chemotherapy, radiation therapy, steroid therapy, or other immunotherapy within the past 4 weeks, 2) presence of other cancers that might influence the prognosis, 3) immunodeficiency or a history of splenectomy, 4) severe cadiac insufficiency, acute infection, or hematopoietic failure, 5) ongoing brest-feeding, 6) unsuitability for the trial based on clinical judgement.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method